Health · Medical Research · 23 hrs ago
Statins linked to lower risk of open-angle glaucoma
A large US study linked statin use with a lower risk of open-angle glaucoma and less intensive treatment for people who already had it.
Statins are medicines prescribed to lower cholesterol and reduce the risk of heart attacks and strokes.
Glaucoma can damage the optic nerve and cause permanent vision loss, often without early symptoms.
Researchers compared health records for more than 421,000 people, half of whom took statins, and studied nearly 60,000 people already diagnosed with glaucoma.
Over five years, 2.3% of statin users developed glaucoma, compared with 2.6% of non-users, a difference the researchers estimated as about 15% lower risk.
People with glaucoma who took statins were also less likely to receive pressure-lowering eye drops or have laser or surgery treatment.
Because this was an observational study, it cannot prove statins caused the lower risk; the findings point to a possible additional benefit, not a proven one.
Statins remain established treatment for reducing cardiovascular risk, and the study does not say people should take them for eye protection.
A large US observational study found that statin use was associated with a lower risk of developing open-angle glaucoma.
Among more than 421,000 people studied, 2.3% of statin users developed glaucoma within five years, compared with 2.6% of those not taking statins.
The researchers also found that people with diagnosed glaucoma who took statins were less likely to receive more intensive treatment.
The study does not show that statins directly prevent glaucoma.
- Who
- A US research team analyzed health records of people with and without statin use.
- What
- Statin use was associated with a lower risk of open-angle glaucoma and less frequent escalation of glaucoma treatment.
- When
- The study was reported on November 2, 2026; the five-year results covered outcomes after the study’s starting point.
- Where
- The researchers used electronic health records from the TriNetX research network in the United States.
- Why
- The researchers examined whether statin use was linked to glaucoma risk and progression; the sources do not state a reason for the association.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Study design
- Retrospective observational cohort study
- Five-year glaucoma rate among statin users
- 2.3%
- Five-year glaucoma rate among non-users
- 2.6%
- Risk difference
- About 15% lower risk among statin users
- Research network
- TriNetX, with 115 health care institutions and 165 million people in its records
- Already diagnosed glaucoma group
- Almost 60,000 people